Net profit of Cipla rose 3.73% to Rs 1351.17 crore in the quarter ended September 2025 as against Rs 1302.53 crore during the previous quarter ended September 2024. Sales rose 6.98% to Rs 7447.42 crore in the quarter ended September 2025 as against Rs 6961.22 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales7447.426961.22 7 OPM %25.4427.09 - PBDT2150.522060.80 4 PBT1853.531789.06 4 NP1351.171302.53 4 Powered by Capital Market - Live News

Cipla will hold a meeting of the Board of Directors of the Company on 30 October 2025.Powered by Capital Market - Live News

Cipla announced that SES ESG Research, a SEBI registered ESG Rating Provider (SES), has independently assigned the Environmental, Social, and Governance (ESG) Rating of 69.3 (Grade B) (Adjusted) from 70.2 (Grade B+) (Adjusted) to the Company.Powered by Capital Market - Live News

Cipla announced that the United States Food and Drug Administration has classified the current Good Manufacturing Practices inspection of the company`s manufacturing facility in Bommasandra, Bengaluru as Voluntary Action Indicated (VAI).Powered by Capital Market - Live News

Net profit of Cipla rose 10.19% to Rs 1297.62 crore in the quarter ended June 2025 as against Rs 1177.64 crore during the previous quarter ended June 2024. Sales rose 3.20% to Rs 6837.04 crore in the quarter ended June 2025 as against Rs 6624.86 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales6837.046624.86 3 OPM %26.0125.90 - PBDT2022.651858.04 9 PBT1769.931611.36 10 NP1297.621177.64 10 Powered by Capital Market - Live News